Observational Study on Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes
This study is looking for adults aged 18 to 65 who have type 2 diabetes and use insulin. The goal is to understand how your body's blood sugar (glucose) and hormones like insulin and glucagon respond after eating a meal. You'll have blood samples taken frequently over a 4-hour period after a standardized liquid meal. You'll also wear continuous glucose monitors and activity trackers at home for about 8 days. The information collected will help researchers create computer models, or "digital twins," to better understand type 2 diabetes. We're hoping to learn more about how these responses change over time.
- Study design
- This is an observational study, meaning there are no interventions or treatments being tested. It plans to enroll 25 participants.
- What's involved
- You will have a screening visit, followed by about 8 days of wearing a continuous glucose monitor and activity tracker at home. Then, you'll have an in-clinic visit for a liquid meal test, which involves frequent blood draws over 4 hours.
- Compensation
- Not stated in the trial record.
- Follow-up
- Blood sugar and hormone levels will be measured for up to 240 minutes (4 hours) after meal consumption during the in-clinic visit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Indika Edirisinghe, Ph.D · PRINCIPAL_INVESTIGATOR · Illinois Institute of Technology
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in Plasma Glucose Concentration (mg/dL)-10 to 240 minutes relative to meal consumption
Plasma glucose concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a clinical chemistry analyzer (Randox). Unit of Measure: mg/dL
- Change in Plasma Insulin Concentration (µIU/mL)-10 to 240 minutes relative to meal consumption
Plasma insulin concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a clinical chemistry analyzer (Randox). Unit of Measure: (µIU/mL)
- Change in Plasma Glucagon Concentration (pg/mL)-10 to 240 minutes relative to meal consumption
Plasma glucagon concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a multiplex immunoassay platform (Luminex). Unit of Measure: pg/mL
- Change in Plasma C-Peptide Concentration (ng/mL)-10 to 240 minutes relative to meal consumption
Plasma C-peptide concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a multiplex immunoassay platform (Luminex). Unit of Measure: ng/mL
- Change in Plasma Triglyceride Concentration (mg/dL)-10 to 240 minutes relative to meal consumption
Plasma triglyceride concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a clinical chemistry analyzer (Randox). Unit of Measure: mg/dL
- Continuous Glucose Monitoring Metrics During Free-Living ConditionsApproximately 8 days during outpatient monitoring
Interstitial Glucose Concentration during Free-Living Conditions via Continuous Glucose Monitor Description: Interstitial glucose concentration measured continuously during outpatient free-living conditions using the Dexcom G7 continuous glucose monitoring device. Unit of Measure: mg/dL
- Average Daily Step Count (steps/day)Approximately 8 days during outpatient monitoring.
Average daily step count, reported in steps per day, measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
- Average Daily Active Minutes (minutes/day)Approximately 8 days during outpatient monitoring.
Average daily active minutes, reported in minutes per day, measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
- Average Daily Sleep Duration (hours/night)Approximately 8 days during outpatient monitoring.
Average sleep duration, reported in hours per night, measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
- Average Resting Heart Rate (beats/minute)Approximately 8 days during outpatient monitoring.
Average resting heart rate, reported in beats per minute (bpm), measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.